CCM
ALXN

Carderock Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Carderock Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,384
Closed -$216K – 101
2014
Q2 		$216K Buy
1,384
+20
+1% +$3.16K 0.11% 93
2014
Q1 		$208K Buy
+1,364
New +$217K 0.11% 94

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Carderock Capital Management's ALXN Position: Q3 2014 in Review

Carderock Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2014, closing a stake of 1,384 shares — an estimated $216K sold.

Carderock Capital Management first reported a position in ALXN in Q1 2014 and held it in 2 quarters. The position peaked at $216K in Q2 2014. 522 funds tracked by Wall St. Rank hold ALXN as of Q3 2014.

  • Carderock Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Carderock Capital Management sold 1,384 Alexion Pharmaceuticals shares in Q3 2014, an estimated $216K.
  • Carderock Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Carderock Capital Management's Alexion Pharmaceuticals position peaked at $216K in Q2 2014.
  • 522 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2014.

Based on Carderock Capital Management's 13F filing for Q3 2014, filed 6 Nov 2014.